Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology

Radionetics’ pipeline is based on a broadly enabling platform and intellectual property that will leverage more than a decade of discovery experience within Crinetics. The platform uses nonpeptides as targeting agents designed to deliver therapeutically active radiopharmaceuticals to tumors expressing unique peptide receptors. Radionetics’ initial drug development efforts will center on advancing a collection of 10 potent nonpeptide-targeted radiopharmaceutical candidates and leads, discovered at Crinetics, into clinical imaging and efficacy studies.

Crinetics Pharmaceuticals Unveils Parathyroid Hormone Receptor Antagonist Program at ASBMR

“Our PTHR1 antagonists have the potential to improve the lives of people with hypercalcemia caused by parathyroid adenomas; and moreover, may offer a life-saving treatment option for patients with CKD or cancer, for whom hypercalcemia is a complication that can be fatal. We look forward to the continued advancement of this preclinical program and to the identification of a lead PTHR1 antagonist for optimization.” - Alan Krasner, M.D., Crinetics’ chief medical officer.

CRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

Alan Krasner, M.D., chief medical officer at Crinetics, added, “We are very encouraged by these single ascending dose data that clearly demonstrate proof-of-SST5 agonism and resultant inhibition of insulin secretion with CRN04777 exposure in healthy volunteers. We are excited by the possibility that CRN04777 may serve as an oral treatment to normalize glucose levels in any child born with congenital HI regardless of their specific genetic mutation and eagerly look forward to better understanding its full potential with additional clinical studies.”

Crinetics Pharmaceuticals to Participate in September Investor Conferences

Crinetics' management will be participating in investor conferences hosted by H.C. Wainwright, SVB Leerink and Cantor Fitzgerald during the month of September.

Crinetics Appoints Jeff Knight as Chief Operating Officer

“Jeff’s intellectual curiosity and proven ability to grow into new roles makes him a natural fit for the Crinetics team. We look forward to applying his specific expertise in operational and clinical management as we continue to advance our pipeline and increase the staff and infrastructure necessary to support the growing clinical and commercial operations.” - Scott Struthers, Ph.D. Founder, CEO - Crinetics